For a study, researchers sought to determine how interim fluorodeoxyglucose positron emission tomography (interim-FDG-PET) responses in high-risk diffuse large B-cell lymphoma (DLBCL) or classic Hodgkin lymphoma (c-HL) were affected by liposomal doxorubicin (NPLD) supercharge-containing treatment.

In the phase II trial (2016-2021), R-COMP-dose-intensified (DI) and MBVD-DI were used as the first-line treatments for 81 adult patients with advanced-stage DLBCL (n = 53) and c-HL (n = 28). R-COMP-DI included 70 mg/m2 of NPLD together with normal doses of rituximab, cyclophosphamide, vincristine, and prednisone for 3 cycles (followed by 3 cycles with NPLD de-escalated at 50 mg/m2); MBVD-DI included 35 mg/m2 of NPLD along with standard doses of bleomycin, vinblastine, and dacarbazine for two cycles (followed by four cycles with NPLD de-escalated at 25 mg/m2). Patients received median dose intensities of 91% and 94% for R-COMP-DI and MBVD-DI, respectively.

An early death prevented 1 patient from undergoing interim-FDG-PET, leaving 72/81 patients with a Deauville score of less than or around 3. However, about 90% of patients had full responses by the time their treatments were through. Overall, 20 individuals experienced Grade more than or around 3 adverse events, and 4 needed to be admitted to the hospital. The overall population’s progression-free survival rate was 77.3% (95% CI 68%-88%) at a median follow-up of 21 months.

The findings indicated that using the NPLD supercharge-driven strategy in phase III trials for increasing the incidence of negative interim-FDG-PET cases in high-risk DLBCL/c-HL may be a potential alternative.